Botulinum toxin and plantar fasciitis

NewsBot · Aug 8, 2023

Clinical efficacy of botulinum toxin type A in the treatment of fasciitis pain: A systematic review and meta-analysis
Tong-Tong Li et al
Medicine (Baltimore). 2023 Jul 28;102(30):e34461

Background: The purpose of this meta-analysis was to assess the effectiveness of botulinum toxin type A (BoNT-A) in reducing pain associated with fasciitis. By synthesizing the findings from multiple studies, we aimed to provide a comprehensive evaluation of the current evidence regarding the efficacy of BoNT-A in the treatment of fasciitis pain.

Methods: To identify studies for our report, we conducted electronic database searches of Embase, PubMed, Web of Science, and the Cochrane Library from their inception to November 20, 2022. We included only randomized controlled trials that examined the therapeutic effects of BoNT-A on fasciitis pain, with the primary outcome measure being the visual analog scale. We conducted statistical analyses using RevMan 5.4 software.

Results: Our final meta-analysis comprised 14 randomized controlled trials involving 537 participants, with 271 patients in the BoNT-A group and 266 patients in the control group. The overall effectiveness of BoNT-A in reducing fasciitis pain was significant, with a mean difference (MD) in visual analog scale score of -2.59 (95% confidence interval [CI], -3.36, -1.82); P < .00001; I2 = 88%. Subgroup analysis revealed that BoNT-A was particularly effective in treating plantar fasciitis (MD = -3.34 [95% CI, -4.08, -2.78]; P < .00001; I2 = 75%), lumbar back fasciitis (MD = -2.17 [95% CI, -3.82, -0.52]; P = .001; I2 = 93%), and neck and shoulder fasciitis (MD = -1.49 [95% CI, -2.76, -0.22]; P = .02; I2 = 61%).

Conclusion: BoNT-A has a significant analgesic effect on fasciitis pain. Therefore, BoNT-A presents a promising alternative treatment option for fasciitis
Click to expand...

NewsBot · Nov 1, 2023

Botulinum toxin A versus platelet rich plasma ultrasound-guided injection in the treatment of plantar fasciitis: a randomised controlled trial
Isabel M. Ruiz-Hernández et al
Foot and Ankle Surgery 14 October 2023

Background
Platelet-rich plasma (PRP) and botulinum toxin type A (BTX-A) injections have proven effective in clinical trials for plantar fasciitis treatment but have not been directly compared. We aimed to compare clinical outcomes in patients undergoing PRP or BTX-A injections.

Methods
We performed a randomised controlled trial (59 patients; 1-year follow-up) to assess efficacy, using pain and functional scales (VAS, AOFAS Hindfoot-scale and FAAM questionnaire) and fascia thickness reduction, in control and single ultrasound-guided BTX-A or PRP injection groups.

Results
The BTX-A group showed better results at 1-month after treatment. Conversely, the PRP injection was more effective in the long-term, with significant pain reduction and functional improvement. Plantar fascia thickness significantly reduced from months 1 and 3 in the PRP and BTX-A groups, respectively.

Conclusion
PRP and BTX-A injections are effective in patients with plantar fasciitis with BTX-A achieving better short-term pain reduction and PRP better long-term results.
Click to expand...

NewsBot · Nov 27, 2023

Botulinum toxin A versus platelet rich plasma ultrasound-guided injection in the treatment of plantar fasciitis: A randomised controlled trial
Isabel M Ruiz-Hernández et al
Foot Ankle Surg. 2023 Oct 14:S1268-7731(23)00192-3

Background: Platelet-rich plasma (PRP) and botulinum toxin type A (BTX-A) injections have proven effective in clinical trials for plantar fasciitis treatment but have not been directly compared. We aimed to compare clinical outcomes in patients undergoing PRP or BTX-A injections.

Methods: We performed a randomised controlled trial (59 patients; 1-year follow-up) to assess efficacy, using pain and functional scales (VAS, AOFAS Hindfoot-scale and FAAM questionnaire) and fascia thickness reduction, in control and single ultrasound-guided BTX-A or PRP injection groups.

Results: The BTX-A group showed better results at 1-month after treatment. Conversely, the PRP injection was more effective in the long-term, with significant pain reduction and functional improvement. Plantar fascia thickness significantly reduced from months 1 and 3 in the PRP and BTX-A groups, respectively.

Conclusion: PRP and BTX-A injections are effective in patients with plantar fasciitis with BTX-A achieving better short-term pain reduction and PRP better long-term results.
Click to expand...

NewsBot · Dec 21, 2024

Therapeutic efficacy and safety of botulinum toxin A injection in plantar fasciitis: A systematic review and meta-analysis
Qian Li,Jing Zhang,Jie Sun,Chengfei Gao,Jing Zhao
December 17, 2024

Objective
The purpose of this meta-analysis was to evaluate the therapeutic efficacy and safety of botulinum toxin A (BTA) injections for treatment of plantar fasciitis (PF).

Methods
This review adhered to the PRISMA guidelines, conducting a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases for eligible studies from their inception to December 30 2023. The inclusion criteria were limited to randomized controlled trials (RCTs) comparing BTA injections with control interventions in terms of pain reduction, functional improvement, or the occurrence of adverse events in treating patients with PF were extracted for meta-analysis. Relevant data were extracted using an electronic spreadsheet and analyzed with Stata 16.0 software. The quality of included studies was assessed using the Cochrane Collaboration’s tool.

Results
A total of 655 studies were retrieved and subsequently screened. Seven RCTs, comprising 305 participants, met the eligibility criteria and were included in the meta-analysis. The pooled results indicated that BTA injections led to significant pain reduction only at 1-month posttreatment (SMD = -1.72, 95% CI [-3.10, -0.34], p = 0.01]) and sustained functional improvement over twelve months (SMD = 25.10, 95% CI [9.67, 40.53], p = 0.001) compared to the control group. There was no significant difference in the occurrence of adverse events between the BTA and control interventions (OR = 0.16, 95% CI [-1.00, 1.32], p = 0.79).

Conclusion
This meta-analysis suggested that BTA injection could be an effective and safe therapeutic strategy for plantar fasciitis. However, further larger-scale, rigorously designed RCTs are needed to validate these findings and determine the optimal injection dosage and site for BTA in the treatment of plantar fasciitis.
Click to expand...

NewsBot · Aug 22, 2025

Botulinum Toxin Type A in the Management of
Plantar Fasciitis: A Step Forward in Pain Relief
Chaimaa Iziki , Sara Skalli , Lina Lahbabi , Naila Haltout , Samia Karkouri
Source

Plantar fasciitis is a prevalent cause of heel pain in adults, particularly among the middle-aged population.
It is characterized by microtrauma that exceeds the regenerative capacity of the plantar fascia. Although
most cases respond well to conservative treatment, such as stretching exercises, orthotic use, and
nonsteroidal anti-inflammatory drugs, some cases progress to chronic stages that require second-line
therapies, including extracorporeal shockwave therapy, corticosteroid or platelet-rich plasma injections, or
surgical plantar fascia release. This review aims to evaluate the efficacy of botulinum toxin type A (BTA)
injections in the management of chronic plantar fasciitis. A narrative review was conducted without any
date restrictions, covering the period from 1994 to 2025, through databases including PubMed, Scopus,
ScienceDirect, and Google Scholar. Included studies focused on patients with plantar fasciitis unresponsive
to conservative treatments, using pain and functional outcomes as endpoints. Three randomized controlled
trials demonstrated that BTA injections significantly reduced pain and improved function across short, mid-,
and long-term follow-ups. BTA acts at the neuromuscular junctions to reduce muscle tone and modulate
pain pathways. BTA injections appear to be a safe and effective option for patients with chronic plantar
fasciitis unresponsive to first-line therapies. Image-guided injections (ultrasound or electromyographic) are
recommended to enhance accuracy. Further research is necessary to establish standardized protocols
regarding the injection site, dosage, guidance technique, and reinjection timing.
Click to expand...

NewsBot · Sep 19, 2025

Botulinum Toxin Type A in the Management of Plantar Fasciitis: A Step Forward in Pain Relief.
Iziki C, Skalli S, Lahbabi L, et al.
Cureus 17(8): e90415. doi:10.7759/cureus.90415

Plantar fasciitis is a prevalent cause of heel pain in adults, particularly among the middle-aged population. It is characterized by microtrauma that exceeds the regenerative capacity of the plantar fascia. Although most cases respond well to conservative treatment, such as stretching exercises, orthotic use, and nonsteroidal anti-inflammatory drugs, some cases progress to chronic stages that require second-line therapies, including extracorporeal shockwave therapy, corticosteroid or platelet-rich plasma injections, or surgical plantar fascia release. This review aims to evaluate the efficacy of botulinum toxin type A (BTA) injections in the management of chronic plantar fasciitis. A narrative review was conducted without any date restrictions, covering the period from 1994 to 2025, through databases including PubMed, Scopus, ScienceDirect, and Google Scholar. Included studies focused on patients with plantar fasciitis unresponsive to conservative treatments, using pain and functional outcomes as endpoints. Three randomized controlled trials demonstrated that BTA injections significantly reduced pain and improved function across short, mid-, and long-term follow-ups. BTA acts at the neuromuscular junctions to reduce muscle tone and modulate pain pathways. BTA injections appear to be a safe and effective option for patients with chronic plantar fasciitis unresponsive to first-line therapies. Image-guided injections (ultrasound or electromyographic) are recommended to enhance accuracy. Further research is necessary to establish standardized protocols regarding the injection site, dosage, guidance technique, and reinjection timing.
Click to expand...

NewsBot · Dec 31, 2025

Botulinum Toxin in the Therapy of Chronic or Relapsing Plantar Fasciitis-A Descriptive Review
Daniela Poenaru et al
Biomedicines. 2025 Oct 28;13(11):2647.

Background. Plantar fasciitis is a degenerative condition that may follow a chronic or recurrent course. Injectable agents are frequently employed to alleviate pain and restore function. Recently, botulinum toxin (BoNT) has gained particular attention for its analgesic properties, positioning it as a promising therapeutic option for the management of plantar fasciitis. Method. We conducted a literature review to evaluate studies on BoNT administration in plantar fasciitis, aiming to define the target tissues, optimal doses, methods of administration, and associated adverse effects. Results. The evidence suggests that BoNT provides significant short- and long-term analgesic benefits when administered either intrafascially or intramuscularly, with outcomes comparable to or exceeding those of corticosteroids. Conclusion. Further high-quality studies are warranted to compare BoNT with other therapeutic modalities, such as PRP and extracorporeal shockwave therapy (ESWT).
Click to expand...

NewsBot · Sep 9, 2026

Ultrasound-guided botulinum toxin injection in patients with chronic plantar fasciitis: comparison of plantar fascia origin injection and the babcock method-a randomized controlled trial
Arezou Darvishi et al
Future Sci OA. 2026 Dec;12(1):2728653.

Aims: To compare the effectiveness and safety of ultrasound-guided botulinum toxin injection at the plantar fascia origin with the two-point Babcock technique in patients with chronic plantar fasciitis.

Materials and methods: This randomized clinical trial compared two ultrasound-guided botulinum toxin injection techniques. Pain intensity, foot function, pressure-pain threshold, and ultrasonographic plantar fascia thickness were assessed at baseline and at 6 and 24 weeks. Between-group comparisons were adjusted for baseline values, and treatment effects were reported with 95% confidence intervals.

Results: Sixty participants were randomized, and 53 completed follow-up. At 24 weeks, the Babcock group showed a greater improvement in Foot Function Index-Revised scores than the plantar-fascia-origin group (adjusted mean difference, -14.18; 95% CI, -20.70 to -7.66; p < 0.001). Pressure-pain threshold was also higher in the Babcock group at 6 weeks (adjusted mean difference, 4.86; 95% CI, 2.65-7.08; p < 0.001) and 24 weeks (7.97; 95% CI, 5.23-10.72; p < 0.001). No significant between-group differences were found for pain intensity at 6 weeks (p = 0.191) or 24 weeks (p = 0.529). No serious intervention-related adverse events occurred.

Conclusions: Both techniques were associated with improvement. The Babcock technique may provide additional functional and pressure-pain benefits, although larger multicenter trials are needed
Click to expand...

Botulinum toxin and plantar fasciitis

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Botulinum toxin for diabetic neuropathic pain

First MPJ disorders treated with Botulinum Toxin

Staphylococcus aureus Toxins and Diabetic Foot Ulcers

Topical cantharidin-podophylotoxin-salicylic acid (CPS) treatment of recalcitrant plantar warts

Botoxing Bunions

Share This Page

Botulinum toxin and plantar fasciitis

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

NewsBot The Admin that posts the news.

Botulinum toxin for diabetic neuropathic pain

First MPJ disorders treated with Botulinum Toxin

Staphylococcus aureus Toxins and Diabetic Foot Ulcers

Topical cantharidin-podophylotoxin-salicylic acid (CPS) treatment of recalcitrant plantar warts

Botoxing Bunions

Share This Page

Useful Searches